Walleye Capital’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
Walleye Capital's VKTX Position: Q3 2026 in Review
Walleye Capital increased its Viking Therapeutics (VKTX) stake by 2,326% in Q3 2026, buying an estimated $9.11M and bringing the position to 274,173 shares worth $8.94M. The position accounts for 0.01% of the portfolio, ranked #1365.
Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 19 quarters since. 439 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.
- Walleye Capital held 274,173 shares of Viking Therapeutics worth $8.94M as of Q3 2026.
- Walleye Capital bought 262,871 Viking Therapeutics shares in Q3 2026, an estimated $9.11M.
- Viking Therapeutics made up 0.01% of Walleye Capital's portfolio in Q3 2026, its #1365 holding.
- Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 19 quarters since.
- 439 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.